SCHEMBL2053259

SCHEMBL2053259

O=C(Cn1cc(Nc2ncnc3cccc(F)c23)cn1)Nc1cccc(F)c1F

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.51
FLT4 P35916 4/20 0.51
FLT3 P36888 3/20 0.51
CSF1R P07333 2/20 0.47
KIT P10721 2/20 0.47
PDGFRA P16234 2/20 0.47
AURKA O14965 3/20 0.47
CYP3A4 P08684 1/20 0.44
TYK2 P29597 4/20 0.41
AURKB Q96GD4 2/20 0.39
KDR P35968 2/20 0.39
CHEK1 O14757 1/20 0.39
RPS6KA3 P51812 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
BTK Q06187 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37
GPR142 Q7Z601 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2052335 0.90 FLT4 (0.60) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL2049522 0.90 PDGFRB (0.54) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL3431197 0.84 FLT3 (0.55) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL3429524 0.84 FLT4 (0.57) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL3427294 0.84 PDGFRB (0.58) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL3424548 0.84 PDGFRB (0.54) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL4642749 0.83 PDGFRB (0.49) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL3429640 0.82 FLT4 (0.49) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL4924577 0.82 FLT4 (0.55) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL2049819 0.82 PDGFRB (0.64) PDGFRBFLT4FLT3CSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4709139-B2 2011-06-22 JP claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US claimed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP claimed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US claimed
JP-2006523660-A 2006-10-19 JP claimed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP claimed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US disclosed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 PDGFRB 1544/4885FLT4 2898/4885FLT3 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.